Physician profile
Eda Augustin
NPI 1669834115
$1,201.17
in general payments reported to CMS, 2019-2025
16 companies · $79.47 in 2025
The $79.47 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $721 · 2022: $38.10 · 2023: $335 · 2024: $27.29 · 2025: $79.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $238.40 | 2021 | |
| Eisai INC. | $149.21 | 2021-2024 | |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Ipsen Biopharmaceuticals, INC | $124.89 | 2021 | |
| Incyte Corporation | $119.75 | 2021 | |
| Amgen INC. | $116.25 | 2021 | |
| Neurocrine Biosciences, INC. | $83.30 | 2023 | Ingrezza |
| Janssen Scientific Affairs, LLC | $50.86 | 2023 | Invega Trinza, Invega Sustenna, Spravato |
| Janssen Biotech, INC. | $33.88 | 2025 | Darzalex, Tecvayli |
| Axsome Therapeutics, INC. | $33.68 | 2023 | Auvelity |
| Pfizer INC. | $25.36 | 2025 | |
| Genzyme Corporation | $23.27 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.89 | 2023 | |
| Stemline Therapeutics INC. | $20.23 | 2025 | Elzonris |
| Janssen Pharmaceuticals, INC | $19.37 | 2023 | Invega Sustenna, Spravato, Invega |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eda Augustin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.